Preoperative Gastric Cancer Immune Prognostic Score (GCIPS) as a Novel Biomarker for Predicting Survival in Gastric Cancer Patients After Radical Resection

Background This study aimed to validate the preoperative Gastric Cancer Immune Prognostic Score (GCIPS) as a prognostic biomarker in resectable gastric cancer (GC). Methods We retrospectively analyzed 226 GC patients undergoing radical resection. The optimal cutoff value of the CALLY index was determined by ROC curve analysis, and patients were stratified accordingly to assess its prognostic value for RFS and OS. Results The GCIPS was calculated from preoperative blood parameters. Using ROC-derived cutoff (2.840), patients were stratified into high- and low-GCIPS groups. The high-GCIPS group showed significantly poorer tumor differentiation (P < 0.001). Kaplan-Meier analysis revealed that high GCIPS was associated with worse 5-year recurrence-free survival (HR = 2.856, P < 0.001) and overall survival (HR = 3.222, P < 0.001). Multivariate analysis confirmed GCIPS as an independent predictor for both outcomes after adjusting for TNM stage and differentiation. Conclusion The GCIPS is a robust, independent prognostic biomarker derived from routine blood tests, offering a practical tool for risk stratification and guiding individualized management in GC after radical resection.